These findings suggest that dopamine (DA) neurons in these two regions are functionally related to intrinsic CCK-containing cortical neurons, and that CCK subsensitivity, perhaps due to an alteration in DA transmission, is involved in MAP sensitization. These findings may be relevant to the DA hypothesis of schizophrenia.
Introduction
The dopamine (DA) hypothesis of schizophrenia has been predominant for the past several decades (Haracz, 1982; Carlton et al., 1984) . This concept is based largely on the clinical evidence that the neuroleptics, DA receptor blockers, are effective in the treatment of schizophrenia and that indirect DA agonists such as amphetamine and phencyclidine can produce or exacerbate psychotic symptoms.
Recently, a close functional interrelationship between dopaminergic (DA) systems and cholecystokinin (CCK) has been demonstrated in certain brain regions (H6kfelt etal., 1980; Studler etal., 1984; Crawley, 1985; Fuxe etal., 1985; Penke etal., 1985; Skirboll and Hommer, 1985; Wang etat., 1985) . Furthermore, accumulating evidence suggests that CCK plays a role in the pathophysiology of schizophrenia and in the therapeutic actions of antipsychotic drugs (Moroji etal., 1982a, b; Nair, 1982; Bloom etal., 1983; van Ree etal., 1984) . Supporting evidence comes from the observations that (1) when compared to normal individuals, CCK concentrations (Ferrier et al., , 1985 Roberts et al., 1983; Vasavan Nair et al., 1985) and CCK receptors Vasavan Nair etal., 1985) in certain brain regions are significantly reduced in schizophrenics; (2) ceruletide, a decapeptide chemically related to have been shown to be effective in the treatment of some chronic neuroleptic-resistant schizophrenic patients in open trials (Moroji etal., 1982a, b; Nair etal., 1982; Bloom etal., 1983) . However, several subsequent single-and double-blind placebo-controlled studies have not yielded consistent results (for review see Mattes et al., 1985; Nair etal., 1986) ; and (3) chronic antipsychotic drug treatment increases the CCK concentration (Frey, 1983) and the number of CCK receptors (Chang et al., 1983; Fukamauchi et al., 1987) .
An amphetamine produces psychotic symptoms that resemble paranoid schizophrenia or a paranoid state, chronic amphetamine-induced psychosis may be a useful model for schizophrenia (Snyder, 1973) . In addition, animal studies have demonstrated that chronic administration of d-amphetamine produces severe stereotypes, followed by inactivity, and then overresponsiveness to environmental stimuli and a series of behavior described as "hallucinatory-like" (Ridley et al., 1982; Ellison and Eison, 1983) . Therefore, it seems Iikely that the chronically amphetamine-treated animal might constitute an animal model for schizophrenia. To elucidate the possible roles of CCK in the pathophysiology of schizophrenia, we investigated the changes in the binding parameters of [propionyl-3H] propionylated CCK-8 binding sites in the rat forebrain following acute and chronic administration of methamphetamine.
Material and methods
Male Wistar strain rats (300-350 g) were used. The animals were housed 2 per cage and maintained in an air-conditioned animal room on a 12-hr-light 12-hr-dark cycle with lights on a 08:00. All animals had access to commercial food and tap water ad libitum.
Methamphetamine (MAP) (Dainippon Seiyaku, Osaka, Japan) was diluted in physiological saline. MAP and physiological saline were injected intraperitoneally (i.p.). In Experiment 1, MAP or physiological saline was injected once at a dose of 4 mg/kg, and in Experiment 2, it was injected daily for 14 days.
All animals were killed by decapitation 24 hr after the final injection of MAP or physiological saline. The development of supersensitivity to the locomotor effects of MAP ("behavioral sensitization") in chronically MAP-treated animals has been confirmed.
Behavioral changes in rats treated with MAP were assessed according to the method (Akiyama et al., 1982) developed by Costall and Naylor (1974) . After each rat was allowed 30min to become acclimatized to the test cage, the effect of MAP was studied on the 1st day of treatment with MAP, and then on days 4, 7, 10, and 14. Behavioural changes were evaluated at 5 or 30min intervals for 120 rain after MAP injection.
Effects of methamphetamine on CCK receptors in the rat brain
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The in vitro quantitative receptor autoradiographical technique using [propionyl-3H] propionylated cholecystokinin octapeptide ([3H]pCCK-8, 50 60 Ci/mmol, Amersham International plc., Buckinghamshire, England) as the radioligand was as described previously (Sekiguchi and Moroji, 1986) . Briefly, forebrain tissue was scraped from slide-mounted tissue sections with a razor blade by reference to the applicable autoradiogram and placed into scintillation vials. After dissolving the tissue in 0.5 ml Protosol (New England Nuclear, Boston, U.S.A.), the scintillation liquid was added and the radioactivity was measured with a liquid scintillation counter (LS 9000, Beckman Instruments Inc., CA). Specific binding was the difference between total binding and that observed in the presence of 0.1 gM ceruletide (Shionogi Comp., Osaka, Japan). In the present study, the 6 regions of the rat forebrain [e.g. the frontal medial cortex, olfactory bulbs (OB), nucleus accumbens (NAc), olfactory tubercles (OT), caudate-putamen (CP) and anterior cingulate cortex] were used for determining the equilibrium apparent dissociation constant [(Kd)app] and the binding capacity (Bmax). These regions corresponded to approximately A 12,130-12,760 gm (OB), A 11,050-12,130gm (frontal medial cortex), A 9,650-9,820gm (NAc and OT) and A 9,620-8,620 ~tm (CP and anterior cingulate cortex) in the stereotaxic atlas of K6nig and Klippel (1967) , respectively. The data were analyzed by Mann-Whitney U-test (two-tailed) for comparison against the control group treated with physiological saline. Autoradiograms were obtained as described elsewhere Moroji, 1984, 1985) . Briefly, the incubated slides were juxtaposed tightly with tritium-sensitive film (U1-trofilm, LKB) and stored at --70 ~ for approximately 3 months. After exposure, the film was developed in Kodak D-19 at 20~ for 5min and then fixed for 10min.
The autoradiograms obtained from 20 gm coronal tissue sections of the rat forebrain were converted to color-coded images using a computer-assisted image device (MCID, Imaging Research Inc., Ontario, Canada). After this conversion, a non-specific binding image was subtracted from its corresponding total binding image, and then a specific binding image (pmol/g: dry tissue weight equivalent value for intact brain grey matter) was obtained using [3H]Micro-scale RPA 501 and 505 (Amersham International pls., Buckinghamshire, England) as a reference.
[3H]Micro-scale RPA 501 and 505 were cut to a thickness of 20 gm by a microtome, respectively.
After staining the tissue sections with cresyl violet, histological identification was carried out according to the stereotaxic atlas of K6nig and Klippel.
Results

The regional distribution of [3HlpCCK-8 binding sites in the forebrain of control rats
As shown in Fig. 1 The (Kd)app and Bmax values in the 6 regions of the rat forebrain were determined by Scatchard analysis. The non-specific binding vs the total binding ranged from 10 to 15%. The (Kd)app values in the 6 regions ranged from 0.87 • 0.14 to 1.08 + 0.05 (Table 1 ). The density of [3H]pCCK-8 binding sites in the control rats was in the order of NAc > OB > frontal medial cortex = anterior cingulate cortex = CP > OT (Table 1) . 
Effects of a single injection of MAP on [3H]pCCK-8 binding sites
After a single administration of 4 mg/kg MAP, the (Kd)app value in the frontal medial cortex and anterior cingulate cortex was significantly reduced by 17% and 28%, respectively, compared to the control value (Tables 2 and 3 , Figs. 2  and 3) . No obvious change in (Kd)app value was found in the other regions. In addition, no change in Bma x value was observed in any region examined.
Behavioral changes induced by chronically administered MAP
As shown in Fig. 4 , the rating score reached a peak 30 rain after MAP injection at every test session. However, the behavioral change induced by MAP injection were manifested much more rapidly and the mean peak values were increased with the number of injections, indicating that repeated administration of MAP induced MAP sensitization. The Bma x value in the frontal medial cortex was also reduced by 13% and showed statistically a tendency to decrease (p < 0.1) compared to the control value. However, no obvious change in the (Kd)app value was found in either region. These two binding parameters in other regions tested were not affected by repeated MAP injections.
Effects of repeated MAP injections on [3H]pCCK-8 binding sites
Discussion
In the initial radioligand binding studies on CCK binding sites, [125I]-BH-CCK-33 was used as the radioligand to characterize CCK binding sites in rat cerebral cortex membrane preparation (Innis and Snyder, 1980; Saito et al., 1980) . However, further study was greatly hindered by a high amount of non-specific binding and rapid degradation of the radioligand. As we demonstrated previously (Sekiguchi and Moroji, 1986) , non-specific binding in the rat brain could be greatly reduced by using slide-mounted tissue sections and [3H]pCCK-8. Consequently, it became possible to characterize CCK binding sites and to The behavioral changes induced by MAP injection were manifested much more rapidly and the mean peak values were increased with the number of injections determine their distribution in rat brain tissue. In the present study, we determined the amount and distribution of the binding sites identified by [3H]pCCK-8 in the rat forebrain after acute and repeated MAP administration. The changes in binding characteristics of [3H]pCCK-8 binding sites will be discussed in connection with the DA hypothesis of schizophrenia. As shown in the data tables, the variance of the interassay in the Bma x and (Kd)app values was found among the control and saline-rats in experiments 1 and 2. The present study was conducted during different seasons, e.g. the control study in the spring (from March to June), experiment 1 in the fall (from September to October) and experiment 2 in the winter (from December to February). This variance of the interassay should not be overlooked. The results obtained in the present study will be discussed. Using rat brain slices, Wirz-Justice (1974) showed a marked seasonal rhythmicity of DA uptake in various brain regions. In addition, Naber etal. (198t) demonstrated seasonal variations in the daily rhythm of striatal DA receptor binding in the rat brain. Considering these findings, the varying results may be partially due to the factor such as the circannual rhythm.
The ratio of non-specific binding to total binding was under 15% in the present study and the (Kd)app value ranged from 0.87 + 0.14 to t.08 • 0.05 in the forebrain of control rats. These findings were similar to those we obtained previously. The regional distribution of [3H]pCCK-8 in the forebrain was also in good agreement with the previous study (van Dijk et al., 1984; Sekiguchi and Moroji, 1986) . However, in the radioligand binding study using brain tissue sections and [3H]pCCK-8, Fukamauchi et al. (1987) reported that the Bma x values were approximately one order of magnitude less than those obtained in the present study. The method they used in the radioligand binding experiment was the same as that used in the present study. The reason for this discrepancy is unknown.
According to the DA hypothesis of schizophrenia, a hyperactive DA system is responsible for at least some of the symptoms associated with this disease (Meltzer and Stahl, 1976; Haracz, 1982; Carlton and Manowitz, 1984) . Furthermore, recent evidence indicates that the therapeutic actions of antipsychotic drugs is related to a reduction of DA activity in the mesolimbic and mesocortical regions rather than in the nigrostriatal area. Particular attention has been drawn to the role of the mesolimbic DA system in schizophrenia.
Chronic MAP administration has been demonstrated to increase DA D 2 receptor binding in the mesolimbic area of the rat brain along with the behavioral sensitization (Akiyama et al., 1982) . Subchronic MAP administration (Watanabe, 1985) , which produces paranoid psychosis in man (Connel, 1958) , has also been found to cause subsensitivity of DA mesolimbic autoreceptors. These findings suggest that DA autoreceptor subsensitivity and DA postsynaptic receptor supersensitivity in some regions of the brain are involved in the pathophysiology of schizophrenia.
Recently, CCK-like immunoreactivity (CCK-LI) has been demonstrated to be co-localized predominately in DA neurons in the ventral tegmental area (VTA), which project to various limbic structures such as the NAc, central amygdaloid nucleus and OT. This suggests that CCK-peptides in the mesolimbic DA neurons modulates DA function and is relevant to the pathophysiology of schizophrenia (H6kfelt et al., 1980) . However, a recent postmortem study on human brains demonstrated that CCK-LI was reduced in the hippocampus, amygdala and temporal cortex of schizophrenic patients with negative symptoms (Ferrier etal., 1983 (Ferrier etal., , 1985 Roberts etal., 1983) . A significant decrease in CCK-LI in the cerebrospinal fluid was also reported in untreated schizophrenics (Verbanck etal., 1984) . Furthermore, 125I-BH-CCK-33 binding sites in postmortem brain membrane preparations were also reported to be reduced in the frontal cortex and hippocampus but not in the amygdala or temporal cortex of schizophrenics compared with controls .
The acute administration of MAP produced hypermotility and caused a significant decrease in the (Kd)app value with no change in the Bmax value in the frontal medial cortex or anterior cingulate cortex. Unlike the mesolimbic DA neurons, the coexistence of DA and CCK-LI has not been demonstrated in mesocortical DA neurons (Studler et al., 1981) and CCK-LI is found within the intrinsic cortical neurons (Fallon and Seroogy, 1985) . This indicates that CCK-LI is a marker for the population of cerebral cortical interneurons (Emson and Hunt, 1981) . The frontal cortex is known to be innervated primarily by DA cells in the medial VTA. The DA innervation to the anterior cingulate cortex seems to arise from the cells in the lateral VTA and/or medial part of the substantia nigra (SN) (Simon et al., 1976; Carter and FiNger, 1977; Lindvall etal., 1977; Fallon and Moore, 1978) . It seems likely that alteration in the mesocortical DA function, as well as in the nigrostriatal/mesolimbic DA function, is involved in behavioral changes induced by the acute administration of AMP (Matthews and Shore, 1984) . Taken together with the finding that CCK-LI is found within intrinsic cortical neurons, the finding that the (Kd)app value of [3H]pCCK-8 binding sites in the frontal medial cortex and anterior cingulate cortex was decreased by the acute administration of MAP without any change in Bma x value, indicates that the DA innervations to these two forebrain structures is functionally related to the intrinsic CCK containing cortical neurons.
The supersensitivity to the locomotor effects of MAP developed in chronically MAP-treated rats. Along with this behavioral sensitization, the Bma x value in the frontal medial cortex showed a tendency to decrease. And that in the anterior cingulate cortex was significantly decreased following the chronic administration of MAP. However, any changes in the (Kd)app values were not observed in either region. No change in Bma x or (Kd)app value was observed in other forebrain structures. The mesocortical DA system has been demonstrated to possess several characteristics different from the nigrostriatal/mesolimbic DA systems, such as higher DA turnover rate, a greatly diminished responsiveness to direct-acting DA agonists and DA antagonists and a lack of tolerance to the effects of chronically administered DA antagonists (Bannon etal., 1983; White and Wang, 1986) . These characteristics may be due to a lack of nerve terminal DA autoreceptors on the mesocortical DA neurons, an important site of physiological and pharmacological modulation of subcortical DA systems (Bannon et al., !983) . The DA innervation to the anterior cingulate cortex also lacks DA autoreceptors; consequently, it responds much like the mesocortical DA systems.
It is of interest that the change in Bma x or (Kd)app value of [3H]pCCK-8 binding sites was limited to the frontal medial cortex and anterior cingulate cortex either with acute or chronic administration of MAP. It is noteworthy that although the frontal cortex DA level in amphetamine(AMP)-pretreated rats was much lower (23.4 or 39.5%) than that in saline-rats, DA utilization in the frontal cortex, but not in the striatum and NAc, was significantly enhanced in rats pretreated with AMP for 10 days, compared to saline-pretreated controls (Robinson etal., 1985) . This prolonged enhancement in frontal cortex DA utilization in AMP-pretreated rats might also be due to a lack of DA autoreceptors. This raises the possibility that enhanced mesocortical DA activity is involved in the behavioral changes associated with AMP-like substances in animals (Robinson et al., 1985) and hence causes an alteration in binding characteristics of [3H]pCCK-8 binding sites in the frontal medial cortex. This contention may apply to changes observed in the anterior cingulate cortex. Fu-kamauchi etal. (1987) reported that in only one experiment, chronic administration of 3 mg/kg MAP increased the Bma x value in the frontal cortex. The disparity between their results and ours may be in part due to the difference in tissue section used. We used the coronal tissue sections corresponding to the anterior frontal cortex (A 11,050-12,130gm in the stereotaxic atlas of K6nig and Klippel) while Fukamauchi etal. used the tissue sections (A8,620-10,300 gm) which do not correspond to the frontal medial cortex.
The chronic administration of haloperidol (HPL), a DA antagonist, has been demonstrated to cause a significant increase in specific I25I-labeled CCK binding sites in the frontal medial cortex and anterior cingulate cortex as well as in the OT and NAc of the guinea pig brain (Chang etal., 1983) . Likewise, increased CCK binding was observed in the same forebrain structures of the guinea pig following VTA lesion (Chang etal., 1983) . These findings suggest that since an increase in the number of receptor sites is regarded as a sign of supersensitivity, the loss of DA function results in CCK supersensitivity. In the present study, behavioural sensitization developed following the chronic administration of MAP, and this chronic treatment was associated with a slight decrease in the Bma x value in the frontal medial cortex but a significant decrease in the anterior cingulate cortex (p < 0.05). These findings indicate that the chronic administration of MAP induces CCK subsensitivity in these two cortical areas.
It is well known that in many species, lesion of the frontal cortex induces functional deficits similar to the predominant symptoms of schizophrenia (Sartorius etal., 1978; Oades, 1982; . The present findings indicate that the down-regulation in CCK binding sites mediated by an alteration in the mesocortical DA activity plays an important role in the behavioral changes associated with MAP sensitization and in the pathophysiology of at least some symptoms associated with schizophrenia or a type of schizophrenia thought to be involved in the mesocortical DA dysfunction. However, the significant decrease in [3H]pCCK-8 binding sites in the anterior cingulate cortex, which indicates that the down-regulation in CCK binding sites in this area, may also be relevant to MAP sensitization. The cingulate cortex anatomically connects with many other cortical areas, including prefrontal, premotor, frontoorbital, inferoparietal and superotemporal areas (Domesick, 1969; Pandya et al., 1981) . In addition, this structure is believed to regulate both attention to sensory stimuli and affective experiences (Baleydier and Mauguiere, 1980) . The effective experiences and/or attentional mechanisms appear to be disturbed in schizophrenia (Bleuler, 1950; McGhie and Chapman, 1961) . Thus, an altered relationship between the cingulate cortex and its anatomically related to cortical structures might be responsible for the affective and attentional disturbances in schizophrenia. Interestingly, Benes and Bird (1987) demonstrated domains or aggregates of neurons in the anterior cingulate cortex of schizophrenic patients, particularly in the region of layer II, which are smaller and separated by wider distances than those observed in the control group. Therefore, the 192 T. Suzuki and T. Moroji down-regulation in CCK-binding sites in the anterior cingulate cortex, perhaps one occurring in relation to an alteration in DA transmission, may also be involved in the symptomatology of schizophrenia. Further studies on the role of CCK in the frontal lobe must be made before the role of this peptide in schizophrenia can be clarified.
In conclusion, our findings indicate that the DA innervations to both frontal medial cortex and anterior cingulate cortex and their functionally related intrinsic CCK containing cortical neurons play an important role in the behavioral sensitization induced by chronic administration of MAP.
